Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia

E. Ogawa, N. Furusyo, M. Murata, H. Ikezaki, T. Ihara, T. Hayashi, K. Toyoda, K. Okada, M. Kainuma, E. Kajiwara, K. Takahashi, T. Satoh, J. Hayashi

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抜粋

Thrombocytopenia in patients with chronic hepatitis C may represent an obstacle for the initiation of antiviral treatment. The aim of this study was to evaluate factors predictive of successful pegylated interferon (PEG-IFN) α2b and ribavirin (RBV) treatment for patients with thrombocytopenia with no history of splenectomy or partial splenic embolization. One hundred and fifty-one chronic hepatitis C patients (genotype 1: n = 110, genotype 2: n = 41) with TCP (<100 × 109/L) at baseline were enrolled. Pretreatment variables included interleukin 28B (IL28B) genotype (rs8099917) and homoeostasis model assessment of insulin resistance score (HOMA-IR). The kinetics of haemoglobin and platelets according to the inosine triphosphatase (ITPA) genotype (rs1127354) were investigated. Sustained virological response (SVR) was significantly more frequent in hepatitis C virus (HCV) genotype 2 (65.9%) than in genotype 1 (34.5%) patients (P < 0.0001). Multiple logistic regression analysis of HCV genotype 1 extracted IL28B TT genotype [odds ratio (OR) 5.97, P = 0.006] and HOMA-IR <2.5 (OR 7.14, P = 0.0016) as significant independent pretreatment predictors of SVR. The analyses of HCV genotype 2 showed that HOMA-IR was significantly related to SVR, but IL28B genotype was not. Patients with ITPA CC genotype showed a significant haemoglobin reduction and lower degree of platelets decrease than those with ITPA CA/AA genotypes. The most common reason for premature discontinuation of treatment was the development of hepatocellular carcinoma (n = 8, 5.3%). In conclusion, HOMA-IR is a useful predictor of SVR for patients with thrombocytopenia infected with HCV genotype 1 or 2 treated with PEG-IFNα2b and RBV. The inclusion of IL28B, ITPA genotypes and HOMA-IR adds valuable therapeutic information.

元の言語英語
ページ(範囲)838-846
ページ数9
ジャーナルJournal of Viral Hepatitis
20
発行部数12
DOI
出版物ステータス出版済み - 12 1 2013

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases
  • Virology

フィンガープリント Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用